UNSPSC 51271615: Oxetacaine or oxethazaine

This classification denotes an anesthetic agent with the molecular formula C28H41N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IP8QT76V17, chemically known as 2,2-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-methylacetamide) but generally known as oxetacaine, which bears US NIH Compound Identifier 4621. European Medicines Agency schedules Oxetacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09516MIG.

UNSPSC 51271615 Oxetacaine or oxethazaine, a Commodity code, encompasses pharmaceutical products including local anesthetic agents procured by state and local health authorities through cooperative purchasing frameworks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body under this code, soliciting generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities. MMCAP coordinates procurement across multiple states, including Oregon, leveraging three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencara), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — to standardize supply chains and pricing across member jurisdictions. Vendors must hold current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certifications, maintain contractual relationships with at least two of the three authorized wholesalers, and carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. Pricing evaluation weights competitiveness at 75 percent and assesses compliance with administrative data formats, electronic data interchange capability, and administrative fee agreements at 5 percent each.

The MMCAP RFP (S1070000015802), issued January 20, 2026 with proposals due March 26, 2026, represents the most recent documented opportunity under this code. Award is expected to take effect July 1, 2026, with a contract term of two years for new responders and optional extensions at MMCAP's discretion. Vendors must provide detailed product information including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, packaging configurations, and manufacturing locations, with all products available in the marketplace by May 15, 2026. The procurement accepts multiple pricing formats — flat price, net price structures (NF30, NF60, NF90), or WAC-minus arrangements — and levies a 3 percent administrative fee on all contract purchases. Performance violations incur penalties ranging from $200 to $1,500 per incident for late reporting, missed onboarding timelines, or improper class-of-trade denials. Geographic activity concentrates in the Upper Midwest and Pacific Northwest through the MMCAP cooperative structure, with no state-level set-aside or disadvantaged-enterprise restrictions identified in the available documentation.